XU SHUICHAN,FULTZ KIMBERLY ELIZABETH,TRAN TAM MINH,XU WEIMING
申请号：
NZ62986014
公开号：
NZ629860A
申请日:
2014.09.02
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed herein it the use of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pytidin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof, in the manufacture of a medicament for the treatment of cancer, wherein the treatment comprises administration of the 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pytidin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof in combination with a second active ingredient selected from: a receptor tyrosine kinase inhibitor, a phosphoinositide 3-kinase pathway inhibitor, a serine/threonine-protein kinase and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase pathway inhibitor, a DNA damaging agent, a DNA damage response agent, a cytoskeleton perturbagen, a protein stability inhibitor and a Bruton&rsquos tyrosine kinase inhibitor to a patient having a cancer.
